Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

s perhaps one of the largest untapped pharmaceutical markets. Currently available drugs prolong the lives of patients with this condition, however, surprisingly little innovative research is being translated to new medicines. With the help of our Medical Advisory Board, we hope to demonstrate the clinical safety and efficacy of CDP-1050 in an efficient and convincing manner to the satisfaction of the medical community and regulatory authorities alike. Eventually, we hope to make the drug available to treat the desperately ill heart failure patients worldwide."

About Heart Failure

Heart failure, a condition characterized by the inability of the heart to effectively pump blood as well as by fluid accumulation in the lungs and other tissues, is suffered by an estimated five million Americans and is responsible for 300,000 deaths in the U.S. annually, according to the National Heart, Lung and Blood Institute. It is the single largest Medicare expense, at a cost of $33.2 billion each year. The five-year mortality rate with heart failure can be as high as 50 percent.

About CDP-1050

CDP-1050 is an investigational drug candidate for the treatment of heart failure. The drug is designed to correct the nitric oxide and redox imbalance in the failing heart and the cardiovascular system. CDP-1050 has a dual mechanism of action; it inhibits the production of excessive reactive oxygen radicals and restores nitric oxide to physiologic levels. The primary therapeutic target is the ryanodine receptor, the main ion channel in the heart that supplies the calcium necessary for the heart to contract. CDP-1050 is expected to enter a Phase 2 clinical trial this year.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... N.M., Dec. 12 Biomoda, Inc. (OTC,Bulletin Board: ... New,Mexico Institute of Mining and Technology (New Mexico ... to collaborate on clinical,studies and the development of ... commercialization of its assay for the early,detection of ...
... mg/Day Dose for PRISTIQ for the ... Treatment of Major Depressive Disorder, COLLEGEVILLE, Pa., ... WYE ), announces that data from,two Phase 3 clinical studies ... patients who received a 50 mg/day dose of PRISTIQ for ...
... expanding pipeline of products to ... treat ophthalmic diseases, ... developing novel therapeutics for the treatment,of ophthalmic diseases announced today ... a strong, international syndicate of new and,existing investors led by ...
Cached Biology Technology:Biomoda Announces Collaborative Agreement With New Mexico Tech 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6Fovea Pharmaceuticals Completes EUR30M Series B Financing 2Fovea Pharmaceuticals Completes EUR30M Series B Financing 3Fovea Pharmaceuticals Completes EUR30M Series B Financing 4
(Date:4/15/2014)... global experts who study the deadliest infectious diseases recognized ... Ksiazek, professors at the University of Texas Medical Branch, ... International Symposium on Filoviruses. The filoviruses include Ebola and ... percent of people infected. The current outbreak of Ebola ... 100 deaths so far. , "This award represents ...
(Date:4/15/2014)... Zealand,s pastoral landscapes are some of the loveliest in ... Many of the country,s pasture soils have become enriched ... which is then eaten by the cattle and sheep ... New Zealand; cadmium-enriched soils being reported worldwide. , The ... levels in meat and dairy products, human health and ...
(Date:4/15/2014)... Sciences (KNAW) has announced the names of five internationally ... (one million US dollars prize money in total). The ... to science. , This year marks the 50th anniversary ... chemist Erwin Chargaff in 1964. , KNAW juries ... laureates: , Christopher M. Dobson, John Humphrey ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3Five scientists awarded prestigious Heineken Prizes 2
... and Molecular Biology of Universitat Autnoma de Barcelona ... with a tendency to cause conformational diseases such ... amyloidotic cardiomyopathy, etc. finally end up causing them. ... 3D structure and studied why these proteins finally ...
... protein found present in all cells in the body could ... at the University of Edinburgh have found that the protein ... in lipid droplets the parts of cells used to ... of invadolysin were linked to reduced amounts of fat deposits. ...
... was a frightening failure in drug safety processes. In ... died after being administered contaminated doses of the common ... in China and discovered with the help of scientists ... pure heparin that is was undetectable to all but ...
Cached Biology News:Mechanism related to the onset of various genetic diseases revealed 2Mechanism related to the onset of various genetic diseases revealed 3Rensselaer leads effort to replace 1 of the most widely used drugs in American hospitals 2Rensselaer leads effort to replace 1 of the most widely used drugs in American hospitals 3
Large-capacity refrigerated incubator chamber holds up to 4 independently-operated shakers. Programmable heat, refrigeration, humidifcation are standard. Photosynthetic operation, optional....
...
... and disposable ESI Chip allow users to ... electrospray mass spectrometers for life science applications. ... to either speed analysis for increased throughput ... or long acquisition times for proteomics and ...
... are optimised for SYBR Green I assays and ... PCR, with the exception of template and primers. ... levels of active SYBR Green I dye and ... buffer that enables detection of low copy number ...
Biology Products: